Company Encyclopedia
View More
name
Design Therapeutics
DSGN.US
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
1.875 T
DSGN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Design Therapeutics shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $6 to $13.

    benzinga_article·
    US
    DSGN
    +6.10%
    benzinga_article·
    US
    DSGN
    +6.10%

    The Nasdaq Biotechnology Index rose over 1% in early trading of U.S. stocks. Among the constituent stocks, Annexon rose 14.04%, Design Therapeutics rose 15.80%, Adaptive Biotechnologies rose 10.89%, Alumis rose 10.27%, and Agios Pharmaceuticals rose 9.44%. Biogen fell 0.97%, Amgen fell 1.28%, Applied Therapeutics fell 2.32%, and Arrowhead Pharmaceuticals fell 2.79%

    Wallstreetcn·
    US
    DSGN
    +6.10%
    US
    ADPT
    +14.03%
    US
    ANNX
    0.00%
    Wallstreetcn·
    US
    DSGN
    +6.10%
    US
    ADPT
    +14.03%
    US
    ANNX
    0.00%

    Design Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

    Design Therapeutics (NASDAQ:DSGN) reported quarterly earnings of ($0.30) per share, surpassing expectations by $0.04. The stock rose to $6.55 with a market cap of $373.02 million. Analysts maintain a 'Sell' rating, with Weiss Ratings issuing a 'sell (d-)' rating. Institutional investors hold 56.64% of shares, with notable increases from Invesco and Bank of America. Design Therapeutics focuses on developing small molecule drugs for genetic diseases using its GeneTAC platform.

    Market Beat·
    US
    DSGN
    +6.10%
    Market Beat·
    US
    DSGN
    +6.10%

    Design Therapeutics Reports Q3 2025 Financial Results

    Design Therapeutics, Inc. (DSGN) reported its Q3 2025 financial results, revealing a net loss of $16.997 million, up from $13.039 million a year prior. Operating expenses rose to $19.311 million due to increased R&D costs. The company, focused on developing GeneTAC molecules for genetic disorders, maintains a strong cash position of $206 million. Looking ahead, Design Therapeutics aims to advance its clinical programs and invest in R&D to achieve key milestones.

    Tip Ranks·
    US
    DSGN
    +6.10%
    Tip Ranks·
    US
    DSGN
    +6.10%

    Design Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    DSGN
    +6.10%
    LB filings·
    US
    DSGN
    +6.10%